Medpace Holdings, Inc. (MEDP) fair value analysis
Nasdaq · Updated 2026-10-19
MEDP price how computed
Forward Fair Value verdict
OvervaluedMEDP is trading at a 10–25% premium to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $618.47
- Sector
- Healthcare
- 12-month range
- $393.42–$630.19
- Market cap
- $17.3B
- From 52-week high
- -1.9%
- Shares outstanding
- 27.9M
- Rank in Healthcare by discount to fair value
- #79 of 108
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
Medpace Holdings, Inc. is a clinical research organization that provides drug development services to pharmaceutical, biotechnology, and medical device companies. The company operates globally, conducting clinical trials and offering related research services across multiple regions worldwide.
MEDP currently ranks #79 of 108 Healthcare stocks by discount to fair value. It has screened as Overvalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $17.3B
- P/E (trailing)
- 36x
- Revenue (TTM)
- $2.78B
- Net margin
- 17.7%
- EPS (TTM)
- $17.06
- Gross margin
- 28.5%
- Debt / equity
- 0.28
- Revenue growth (3-yr avg)
- 14.5%
- Shares outstanding
- 27.9M
Derived indicators how computed
- Quality grade
- B
- Margin trend
- Contracting
- 52-week position
- The top quarter of its range
- DCF cross-check
- Overvalued
Technicals how computed
- RSI (14-day)
- 52 · neutral
- 50-day average
- $606.40
- 200-day average
- $526.17
- Moving-average state
- 50-day above 200-day (golden cross state); price above both averages
Earnings how computed
- Last 8 quarters vs consensus
- 8 beat, 0 missed
- Quarter by quarter
- 2026-06 ▲ beat (+4.2%)
2026-03 ▲ beat (+8.1%)
2025-12 ▲ beat (+11.7%)
2025-09 ▲ beat (+8.1%)
2025-06 ▲ beat (+3.3%)
2025-03 ▲ beat (+19.5%)
2024-12 ▲ beat (+18.1%)
2024-09 ▲ beat (+4.9%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 2 buy · 11 hold · 1 sell (14 analysts)
- Consensus lean
- Hold-leaning
- Consensus price target
- $596
- Target vs last price
- -3.6%
What our data shows for MEDP
- Our model validated 17 trailing price-to-earnings windows for MEDP, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $393.42–$630.19.
- The 14-day relative strength index sits at a neutral 52.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for MEDP
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent MEDP news
TickrTrends' derived news-sentiment signal for MEDP is currently leaning positive, computed from recent coverage.
- A Look at Medpace Holdings Inc (MEDP) After 6.4% Gain -- GF Value $539.19 vs Price $662.48 (gurufocus.com, 2026-10-21)
TickrTrends take: MEDP is trading at $662 compared to its GF Value estimate of $539, representing a significant premium above the intrinsic value calculation. The Healthcare sector stock's current TickrTrends verdict of Overvalued aligns with this valuation gap, suggesting the market price substantially exceeds the fundamental value assessment. Investors focused on valuation metrics should monitor whether the company's financial performance can justify the premium pricing, or whether a convergence toward the estimated fair value may occur. - Medpace: A Shorter, Cleaner Backlog Is Being Mistaken For A Smaller One (NASDAQ:MEDP) (seekingalpha.com, 2026-10-13)
TickrTrends take: MEDP operates in the Healthcare sector with a current TickrTrends valuation verdict of Overvalued. The distinction between backlog quality and backlog size matters for valuation assessment, as a shorter, cleaner backlog could indicate improved execution efficiency rather than diminished future revenue opportunity. Investors focused on valuation should monitor whether MEDP's operational improvements translate into margin expansion and cash generation that could justify current pricing, or whether the market is overestimating the value of these changes. - Medpace Holdings Inc (MEDP) Shares Surge 3.5% -- What GF Score of 96 Tells Investors (gurufocus.com, 2026-10-05)
TickrTrends take: Medpace Holdings operates in the Healthcare sector and currently trades at a valuation level that TickrTrends has identified as overvalued. The recent share surge follows a strong GF Score rating, which measures fundamental quality; however, valuation-focused investors should note that price appreciation combined with an overvalued designation suggests the stock may have limited margin of safety at current levels. Investors monitoring MEDP should track whether the stock's valuation metrics normalize or whether operational fundamentals strengthen sufficiently to justify the current price.
More MEDP news
- Medpace Holdings Inc (MEDP) Shares Fall 4.2% -- What GF Score of 97 Tells Investors (gurufocus.com, 2026-10-01)
What people are saying
Follow the MEDP conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for MEDP showed a shift in the 50/200-day trend state from mixed to uptrend this week. The stock's current valuation verdict remains overvalued. Despite the positive momentum signal from the uptrend development, the overvaluation assessment suggests the recent price movement may not reflect underlying fundamental value.
- 2026-10-05 — TickrTrends' derived indicators for MEDP showed movement this week within the Healthcare sector. The 50/200-day trend state shifted from uptrend to mixed, while the sector discount rank improved from number 97 to number 92. The current valuation verdict remains overvalued.
- 2026-09-28 — TickrTrends' derived indicators for MEDP showed a shift this week, with the 50/200-day trend state moving from mixed to uptrend. The stock currently carries an overvalued verdict according to the service's valuation assessment. This change reflects a more positive near-term technical positioning despite the existing overvaluation status.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is MEDP stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), MEDP is trading at a 10–25% premium to estimated fair value and screens as overvalued. The exact fair value and discount are available to subscribers.
What is MEDP's TickrTrends verdict?
MEDP's current verdict is Overvalued, refreshed with every weekly Forward Fair Value run.
How does MEDP compare to other Healthcare stocks?
MEDP ranks #79 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is MEDP overbought or oversold?
MEDP's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does MEDP usually beat earnings estimates?
Over its last 8 reported quarters MEDP beat the consensus estimate 8 times and missed 0 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about MEDP?
Of 14 analysts covering MEDP, 2 rate it a buy, 11 a hold and 1 a sell - hold-leaning, with a consensus price target of $596 (-3.6% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
MEDP vs ABBV · MEDP vs AMGN · MEDP vs AZTA · MEDP vs BIO · MEDP vs CAH